Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00801684 · ClinicalTrials.gov registry record · Phase 2
ALK27-001: A Study of Trospium Inhalation Powder (TrIP)Administered to Subjects With COPD
A Phase 2 study, sponsored by Alkermes.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT00801684 is a Phase 2 study that has completed, run by Alkermes. The registered enrollment target is 24 participants.
The verdict
NCT00801684, a Phase 2 study, has completed, sponsored by Alkermes.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study was to evaluate the efficacy, safety, and tolerability of single doses of trospium inhalation powder (TrIP) administered to subjects with chronic obstructive pulmonary disease (COPD).
Interventions
- DRUG Placebo
- DRUG TrIP-2D
- DRUG TrIP-2SS
- DRUG TrIP-2SS + Foradil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2009-02 |
| Est. Completion | 2009-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00801684
The ClinicalTrials.gov registry entry for NCT00801684 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alkermes, which has 66 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00801684 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00801684 about?
NCT00801684 is a clinical study titled "ALK27-001: A Study of Trospium Inhalation Powder (TrIP)Administered to Subjects With COPD". The purpose of this study was to evaluate the efficacy, safety, and tolerability of single doses of trospium inhalation powder (TrIP) administered to subjects with chronic obstructive pulmonary disease (COPD).
What is the current status of trial NCT00801684?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2009-02. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00801684?
The interventions under investigation include: Placebo (DRUG), TrIP-2D (DRUG), TrIP-2SS (DRUG), TrIP-2SS + Foradil (DRUG).
Who is sponsoring clinical trial NCT00801684?
This trial is sponsored by Alkermes, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.